combining molecular and clinical data to predict survival & transformation risk in patients with mds
Published 1 year ago • 28 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
2:45
a personalized prediction model to risk stratify patients with mds
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
9:25
improving mds management: new targets, drug combinations, and personalized and cellular therapies
-
3:31
relevance of the ipss-r during sct in patients with mds in the molecular classification era
-
3:16
developing patient-specific mrd markers for predicting and preventing mds relapse post-sct
-
1:16
the potential of combining pyrimethamine with venetoclax in hma-resistant mds
-
1:45
how should we utilizing molecular data to improve all treatment?
-
2:47
molecular background studies to aid diagnosis and treatment of mds
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
1:06
derive trial update: did vs dvd in newly diagnosed mm
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
0:47
overview of the phase iii enhance trial schema
-
1:52
implementing ai in hematology and the challenges this will overcome
-
1:40
updates on the use of molecular monitoring to detect mrd in aml